Screener
Zevra Therapeutics, Inc. ZVRA Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current portion of discount and rebate liabilities | 11,777 | 12,188 |
| Current portion of income tax payable | 20,844 | 13,710 |
| Other current liabilities | 1,423 | 1,362 |
| Total current liabilities | 48,632 | 39,277 |
| Long-term debt | — | 61,928 |
| Warrant liability | 13,165 | 9,575 |
| Income tax payable | 7,206 | 7,029 |
| Operating lease liabilities, less current portion | 870 | 859 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s total current liabilities?
- Zevra Therapeutics, Inc. (ZVRA) reported total current liabilities of $48.63M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Zevra Therapeutics, Inc.'s total current liabilities increased by 68.7% year-over-year, from $28.83M to $48.63M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s total current liabilities has grown at a 39.1% compound annual growth rate (CAGR), from $7.54M to $39.28M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Zevra Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude